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Multiple studies have addressed deep vein thrombosis chemoprophylaxis timing in traumatic brain injuries.
However, a precise time for safe and effective chemoprophylaxis is uncertain according to experts. A
comprehensive literature review on brain injuries was performed to delineate temporal proportions for 1)
spontaneous intracranial hemorrhage (ICH) progression, 2) post-chemoprophylaxis ICH expansion, and 3)
post-chemoprophylaxis deep vein thrombosis. Twenty-three publications were found including more than 5,000
patients. Spontaneous ICH expansion at 24 hours was 14.8% in 1,437 patients from chemoprophylaxis studies and
29.9% in 1,257 patients not in chemoprophylaxis studies (P < 0.0001). With low-risk ICH (n = 136), 99% of spontaneous
ICH expansion occurred within 48 hours. In moderate or high-risk ICH (n = 109), 18% of spontaneous ICH expansion
occurred after day 3. If patients with pre-chemoprophylaxis ICH expansion are included, the post-chemoprophylaxis
ICH expansion proportion was 5.6% in 1,258 patients with chemoprophylaxis on days 1 to 3 and was 1.5% in 401 with
chemoprophylaxis after day 3 (P = 0.0116). If patients with pre-chemoprophylaxis ICH expansion were excluded,
the post-chemoprophylaxis ICH expansion proportion was 3.1% in 1,570 patients with chemoprophylaxis on days 1
to 3 and was 2.8% in 582 with chemoprophylaxis after day 3 (P = 0.7769). In diffuse axonal injury (n = 188), the
post-chemoprophylaxis ICH expansion proportion was 1.6% with chemoprophylaxis after day 3. The deep vein
thrombosis proportions were as follows: chemoprophylaxis on days 1 to 3, 2.6% in 2,384 patients; chemoprophylaxis
on days 4 or 5, 2.2% in 831; and chemoprophylaxis on day 8, 14.1% in 99 (P < 0.0001). Spontaneous ICH expansion
proportions at 24 hours substantially vary between chemoprophylaxis and non-chemoprophylaxis studies. Chemoprophylaxis
should not be given within 3 days of injury for moderate-risk or high-risk ICH. Chemoprophylaxis is reasonable when low-risk
patients have not developed ICH expansion within 48 hours post-injury. Chemoprophylaxis is also acceptable after day
3, when low-risk patients develop ICH expansion within 48 hours post-injury. In diffuse axonal injury patients who have
not developed ICH within 72 hours, chemoprophylaxis is reasonable. Deep vein thrombosis proportions significantly
increase when chemoprophylaxis is withheld for greater than 7 days.Introduction
Multiple publications have addressed the issue of timing
of deep vein thrombosis (DVT) chemoprophylaxis in
traumatic brain injury (TBI) patients [1]. This literature
has been complemented with a 2010 decision analysis,
published in Critical Care [2]. In 2012, Phelan object-
ively summarized the primary issues regarding the ad-
ministration of chemoprophylaxis in TBI patients [1].
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stated.for the optimal use of chemoprophylaxis in these patients.
Of concern is an earlier publication documenting that
54% of TBI patients developed DVT [3]. The primary clin-
ical concern is that the administration of chemoprophy-
laxis may cause intracranial hemorrhage (ICH) expansion
and the potential for neurologic deterioration [1]. A
substantial percentage of TBI patients will undergo spon-
taneous (non-chemoprophylaxis-related) ICH expansion,
an observation often related to the magnitude of the initial
ICH [4-7]. Phelan described the notion of an early time
period when the risk for spontaneous ICH expansion
should prohibit chemoprophylaxis administration. Hetral. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly cited. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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time when the spontaneous and post-chemoprophylaxis
ICH expansion risks are minimal, delays in chemoprophy-
laxis administration may be associated with unacceptably
high DVT proportions. Therefore, Phelan suggested
that a more qualitative assessment of these risky and
safe time points is needed to assist clinicians with ap-
propriate chemoprophylaxis administration. Numerous
studies indicated the proclivity of previous investigators
to consider ICH as an all-or-none phenomenon; yet,
additional literature indicated that the propensity for
spontaneous ICH expansion differs according to varying
ICH traits. Hence, repeated emphasis is placed on the
need for clinicians to understand that the risk for spon-
taneous ICH expansion is variable, which suggests that
the appropriate time for chemoprophylaxis administration
should also differ.
The Brain Trauma Foundation suggests that low molecu-
lar weight heparin (LMWH) or low-dose unfractionated
heparin should be used with mechanical prophylaxis to
prevent TBI DVT [8]. However, there is insufficient evi-
dence to support specific recommendations regarding
the preferred agent, dose, and timing of pharmacologic
prophylaxis for DVT.
Our aim was to review the published literature for evi-
dence that addresses four issues regarding chemoprophy-
laxis in patients with TBI. The first major objective was to
collate post-chemoprophylaxis ICH expansion and DVT
proportions according to the post-injury day of chemo-
prophylaxis administration. Second, we aimed to deter-
mine whether unfractionated heparin or LMWH is more
efficacious or harmful, compared with the other. Third,
we assessed the impact of routine venous surveillance on
DVT proportions. Finally, we sought to determine the
ubiquity with which intermittent pneumatic compression
devices were utilized in relevant TBI cohorts assessing
DVT complications.
Review methods
Literature search and level of evidence assessment
The initial search spanned a 10-year period (2003 to
2012) and was performed in PubMed using Medical
Subject Heading (MeSH) terms. ‘Head injuries’ and
‘Intracranial hemorrhage, traumatic’ were the two pri-
mary MeSH categories. Each primary MeSH term was
combined with each of the following secondary MeSH
terms: ‘Anticoagulants’, ‘Enoxaparin’, ‘Heparin’, ‘Venous
thromboembolism’, and ‘Venous thrombosis’. PubMed
searches were performed, using all 10 combinations of
the primary and secondary MeSH terms. With each
interrogation, all potentially relevant review articles and
investigations were assessed. When the abstract content
suggested possible significance, the manuscript was ob-
tained and reviewed. Manuscripts of investigations wereassessed to determine if relevant information existed
within the publication. Further, the bibliography of
relevant investigations was reviewed to find additional,
potentially germane studies. Finally, appropriate review
article bibliographies were evaluated to identify additional
studies that might contain pertinent information. The
level of evidence was classified for each article selected for
inclusion in the review [9].
Spontaneous intracranial hemorrhage expansion
investigations
Multiple data results were considered relevant for inves-
tigations assessing spontaneous traumatic ICH expan-
sion proportions. These data included the inclusion and
exclusion criteria, patient injury traits, and the percent-
age of the cohort with ICH. Patient injury traits included
admission Glasgow Coma Score (GCS), Injury Severity
Score, head Abbreviated Injury Score (AIS), the Marshall
score, and magnitude of the initial ICH. Spontaneous
ICH expansion proportions with timelines were deemed
essential. Investigations were stratified and assessed accord-
ing to whether there was intent to assess for chemoprophy-
laxis sequelae. ICH proportions were those as described in
the results section of each manuscript.
Post-chemoprophylaxis intracranial hemorrhage
expansion proportions
Several data outcomes were considered pertinent for
studies assessing post-chemoprophylaxis traumatic ICH
expansion proportions. These data included the inclu-
sion and exclusion criteria, patient injury traits, and the
percentage of the cohort with ICH. ICH proportions were
those as described in the results section of each manu-
script. Patient injury traits included admission GCS, Injury
Severity Score, head AIS, the Marshall score, and mag-
nitude of the initial ICH. Post-chemoprophylaxis ICH
expansion proportions were considered as critical infor-
mation. Investigations were categorized and evaluated ac-
cording to whether pre-chemoprophylaxis ICH patients
were included or excluded in the cohort analysis. The
chemoprophylaxis agents administered were classified as
unfractionated heparin, LMWH, or either. The time of
chemoprophylaxis administration was deemed to be
essential and was documented as a categorical time or,
preferably, according to the precise time (hours or days
post-injury), if documented.
Deep vein thrombosis proportions
Because DVT proportions were described for most of
the studies investigating post-chemoprophylaxis ICH
expansion, these estimates were considered to be the
most relevant for the current analysis. The proportion of
DVT occurrence, as reported in each results section, was
considered as the most essential documented finding. The







Arnold et al. [28] No Yes 3
Cothren et al. [21] Yes No 5
Depew et al. [22] No Yes 4
Dudley et al. [17] No Yes 4
Kim et al. [18] No Yes 4
Kleindienst et al. [23] No No 5
Koehler et al. [19] No Yes 4
Kurtoglu et al. [20] Yes Yes 3
Levy et al. [11] No Yes 3
Minshall et al. [12] No Yes 3
Norwood et al. [24] Yes No 5
Norwood et al. [13] Yes No 5
Norwood et al. [14] Yes No 5
Pahatouridis et al. [25] Yes No 5
Phelan et al. [26] Yes Yes 3
Saadeh et al. [15] No Yes 4
Salottolo et al. [27] No Yes 3
Scudday et al. [29] No Yes 3
Non-CP studies
Bee et al. [4] No Yes 4
Chang et al. [5] No Yes 3
Park et al. [6] No Yes 3
Phelan [16] Yes Yes 3
Velmahos et al. [7] No Yes 3
CP, chemoprophylaxis.
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unfractionated heparin, LMWH, or either. The time of
chemoprophylaxis administration was documented as a
categorical time or, preferably, according to the precise
time, when available. Each article describing a DVT pro-
portion was assessed for documentation in the methods
section that intermittent pneumatic compression devices
were utilized and whether DVT surveillance was routine.
Statistical analysis
When event proportions from individual studies were
combined, the number of patients assessed in each study
was summed and the number of patients with an event
in each study was totaled. The combined event propor-
tion was the total number of patients with an event
divided by the total number of patients under observa-
tion. Combined event proportions were compared with
other combined event proportions, according to differ-
ences in an intervention or an alternative characteristic.
Intergroup event proportions were compared using
Chi-square or Fisher’s exact testing, as appropriate.
Epi Info™ 7.0.9.7 (Centers for Disease Control and Preven-
tion, Atlanta, GA, USA, 2012) was utilized to perform
intergroup event proportion statistical analyses.
Review results
Literature search and levels of evidence
A summary of the literature search process is described
in Table 1. A study by Kwiatt and colleagues [10] was
identified as potentially relevant; however, it was not
included in the analysis because 20% of the patients pre-
sented in earlier reports were included in our analysis.
The review includes 23 studies, with the following levels
of evidence: 11 level 3 studies, 6 level 4 studies, and 6
level 5 studies (Table 2).
Spontaneous intracranial hemorrhage expansion
proportions
Spontaneous ICH expansion proportions come from
studies investigating DVT chemoprophylaxis outcomes
and from other investigations where there was no intent
to assess chemoprophylaxis sequelae. Of the five chemo-
prophylaxis cohorts, spontaneous ICH expansion at 24
hours was 14.8% and included 1,437 patients [11-15]. InTable 1 PRISMA 2009 flow table
Number Reasons
Records identified through PubMed 595
Records after duplicates removed 321
Records screened 321
Full-text articles assessed for eligibility 44
Full-text articles excluded 20 No pertinent data
Studies included in quantitative synthesis 23the investigations without intent to assess the impact of
chemoprophylaxis, spontaneous ICH expansion at 24
hours was 29.9% in eight cohorts that included 1,257
patients [4-7,16]. The spontaneous ICH expansion pro-
portion was significantly different (P < 0.0001; odds ratio
2.5 (95% confidence interval (CI) 2.0 to 3.0). Of the five
chemoprophylaxis cohorts, the initial ICH proportion
was ≤50% in one study [11], not documented in another
investigation [14], approximately 85% in a third study
[12], and 100% in the remaining two studies [13,15]. For
the three studies that documented an ICH ≥85% on the
initial computed tomography (CT) scan, the ICH expan-
sion proportion at 24 hours was 13.5% (77/572) [12,13,15].
For the non- chemoprophylaxis studies, virtually all
patients initially had an ICH.
Spontaneous ICH expansion proportions, with delin-
eated timelines, were presented in a publication by Phelan
and colleagues [16]. Low-risk ICH traits were epidural or
subdural hematoma <9 mm, cerebral contusion <2 cm,
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morrhage with a negative CT angiography, and intra-
ventricular hemorrhage <2 cm in maximum diameter.
Moderate-risk ICH was an ICH that was a greater degree
of hemorrhage than that described for the low-risk cri-
teria. High-risk ICH included patients who required a cra-
niotomy or intracranial pressure monitoring. Of the 136
with low-risk ICH, ICH expansion occurred in 34 (25.0%),
where the ICH expansion was at its largest size by 48
hours post-injury in 98.5%. Of the 42 with moderate-
risk ICH, ICH expansion occurred in 18 (42.9%), where
ICH expansion was not at its largest size until after 72
hours post-injury in 22.2% (4/18) (95% CI 9.0 to 45.2%).
Of the 67 with high-risk ICH, ICH expansion occurred in
43 (64.2%), where the ICH expansion was not at its max-
imal size until after 72 hours post-injury in 16.3% (7/43)
(95% CI 8.1 to 30.0%).
Post-chemoprophylaxis intracranial hemorrhage
expansion proportions
The comprehensive literature search found 26 cohorts
in 18 studies (4,005 patients) that described ICH expan-
sion proportions following chemoprophylaxis. Table 3
summarizes select traits for patients in studies that re-
ceived chemoprophylaxis and included some patients
with pre-chemoprophylaxis ICH expansion. The table
includes: the percentage of patients with ICH, when
known; admission GCS, head AIS or Injury Severity Score;
reasons for study exclusion; and initiation time for chemo-
prophylaxis, when relevant. Table 4 summarizes specified
traits for patients in studies that received chemoprophy-
laxis and excluded all patients with pre-chemoprophylaxis
ICH expansion. The table includes: the percentage of
patients with ICH, when known; admission GCS, head AIS
or Marshall score; other reasons for study exclusion; and
initiation time for chemoprophylaxis, when relevant. Table 5
delineates select study characteristics and outcomes: 1)Table 3 Patient traits for chemoprophylaxis studies that inclu
Study ICH percentage GCS/hAIS
Dudley et al. [17] NR GCS 7
Kim et al. [18] 100 GCS 9, hAIS >
Koehler et al. [19] 100 hAIS 3.7
Koehler et al. [19] 100 hAIS 3.9
Kurtoglu et al. [20] 90 GCS 3-8
Levy et al. [11] ~50 hAIS 4
Minshall et al. [12] 85 hAIS 3.8
Minshall et al. [12] 85 hAIS 4.1
Saadeh et al. [15] 100 NR
Saadeh et al. [15] 100 NR
CP, chemoprophylaxis; CT, computed tomography; GCS, Glasgow Coma Score; hAIS, he
pressure; LOS, length of stay; NR, not reported.whether patients with pre-chemoprophylaxis ICH expan-
sion were included or excluded; 2) chemoprophylaxis
agent; 3) day of chemoprophylaxis initiation; 4) cohort
size; and 5) proportion of post-chemoprophylaxis ICH
expansion. For studies that included some patients
with pre-chemoprophylaxis ICH expansion, the post-
chemoprophylaxis ICH proportion was 5.6% (70/1,258)
when chemoprophylaxis was given on post-injury days 1 to
3 [11,12,15,17-20]. A single study, which included some
patients with pre-chemoprophylaxis ICH expansion,
showed that the post-chemoprophylaxis ICH proportion
was 1.5% (6/401) when chemoprophylaxis was given after
post-injury day 3 [19]. The proportion of difference for
chemoprophylaxis at days 1 to 3 versus after day 3 was sig-
nificant (P = 0.0116; odds ratio = 3.9 (95% CI 1.6 to 9.0%)).
For studies that excluded all patients with pre-chemo-
prophylaxis ICH expansion, the post-chemoprophylaxis
ICH proportion was 3.1% (49/1,570) when chemoprophy-
laxis was given on post-injury days 1 to 3 [11,13,14,21-27].
For studies that excluded all patients with pre-chemo-
prophylaxis ICH expansion, the post-chemoprophylaxis
ICH proportion was 2.8% (16/582) when chemoprophy-
laxis was given after post-injury day 3 [22,26,28,29]. The
proportion difference for chemoprophylaxis at days 1 to 3
versus after day 3 was not significant (P = 0.7769). One
study investigating diffuse axonal injury (n = 118) found
that any ICH expansion occurred within 72 hours post-
injury [19]. When chemoprophylaxis was given at day 4,
the investigators found that the post-chemoprophylaxis
ICH expansion proportion was 1.6%. Post-chemopro-
phylaxis ICH expansion was greater with unfractionated
heparin (9.2%; 20/218) [12,18] compared with LMWH
(3.9%; 126/3,204) (P = 0.0008) [11-15,17,19-21,23-27].
Deep vein thrombosis proportions
Because DVT proportions were described for most of
the studies investigating post-chemoprophylaxis ICHded those with early increased intracranial hemorrhage
Exclusions CP day
None relevant 3




Hospital LOS <3 days 3
Hospital LOS ≤48 hours 47 hours
Hospital LOS ≤48 hours 55 hours
Hospital LOS <3 days; no repeat CT 2
Hospital LOS <3 days; no repeat CT ≥3
ad Abbreviated Injury Scale score; ICH, intracranial hemorrhage; ICP, intracranial
Table 4 Patient traits for chemoprophylaxis studies that excluded those with early increased intracranial hemorrhage
Study ICH percentage GCS/hAIS Other exclusions CP day
Arnold et al. [28] 100 NR DAI; cerebral edema; craniotomy -
Cothren et al. [21] NR GCS 3-7 systemic anticoagulation; diagnosis of DVT;
placement of vena cava filter
-
Depew et al. [22] 100 MS ≥2 Mass-effect -
Kleindienst et al. [23] 36 NR None; 16% of candidates excluded -
Levy et al. [11] ~50 hAIS 4 Hospital LOS <3 days 3
Norwood et al. [24] NR GCS 3-8 LOS <3 days; ISS <9; spinal cord injury; coagulopathy;
LMWH not at appropriate time; no duplex scan
at discharge; high risk for bleeding
-
Norwood et al. [24] NR hAIS ≥2 See above -
Norwood et al. [13] 100 GCS 10.0, hAIS 3.6 LOS <2 days; coagulopathy; expected brain death -
Norwood et al. [14] NR GCS 10.4, hAIS 3.6 Surgeon reluctance despite meeting criteria n = 24%;
large ICH; persistent ICP >20; expected brain death;
hospital LOS <3 days; solid organ injury; spinal cord
hematoma; coagulopathy; pre-injury antithrombotic
-
Pahatouridis et al. [25] NR GCS 9-12 Extra-cranial injury; surgery; coagulopathy -
Phelan et al. [26] 96 GCS 13.5 Large ICH; persistent ICP >20 torr 1
Phelan et al. [26] 93 GCS 13.0 Large ICH; persistent ICP >20 torr 4
Salottolo et al. [27] NR GCS ≤8 (29%), hAIS 3.5 Hospital LOS <3 days; death in 7 days; IVC filter;
pre-injury antithrombotic
-
Scudday et al. [29] NR GCS >9 (50%), hAIS 3.4 Craniotomy; hospital LOS ≤3 days -
Dashes in the ‘CP day’ column indicate no ICH percentage, GCS, hAIS, or patient exclusion variance according to day of CP administration. CP, chemoprophylaxis;
DAI, diffuse axonal injury; DVT, deep vein thrombosis; GCS, Glasgow Coma Score; hAIS, head Abbreviated Injury Scale score; ICP, intracranial pressure; ICH,
intracranial hemorrhage; ISS, Injury Severity Score; IVC, inferior vena cava; LOS, length of stay; LMWH, low molecular weight heparin; MS, Marshall score; NR,
not reported.
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dence. These comprised 28 cohorts in 15 studies (4,491
patients; Table 6). Table 6 delineates select study cha-
racteristics: 1) chemoprophylaxis agent used (unfractio-
nated heparin, LMWH, or either); 2) lower extremity
compression device use; 3) chemoprophylaxis day of ad-
ministration; 4) cohort size; and 5) DVT proportion.
Intermittent pneumatic compression devices were used
in 78.6% (22/28) of the cohorts and one cohort used
compression stockings (Table 6). However, there was no
statement regarding lower extremity compression devices
for the other five cohorts (Table 6). Table 7 delineates the
DVT proportions for patients where 1) chemoprophylaxis
was never considered appropriate [11,12,20,22,27,29], 2)
chemoprophylaxis was given on post-injury days 1 to 3
[12-15,17-20,22,23,26,27], 3) chemoprophylaxis was given
on post-injury day 4 or 5 [19,26,29], and 4) chemoprophy-
laxis was given on post-injury day 8 [28]. The DVT pro-
portion for chemoprophylaxis on day 8 was significantly
higher than for the other groups (P < 0.0001). The DVT
proportion for patients receiving unfractionated heparin
was 4.6% (13/282) [12,18,28], whereas the DVT propor-
tion for patients receiving LMWH was 2.8% (79/2,812)
(Table 6) [11-15,17,19,20,23,26-28]. The DVT proportion
with unfractionated heparin (4.6%) was not statistically
different from the LMWH proportion (2.8%; P = 0.0968).For patients receiving chemoprophylaxis and undergoing
routine DVT scanning, the DVT proportion was 5.4%
(37/682; Table 6) [11,18,20,22,27]. For patients re-
ceiving chemoprophylaxis and not undergoing routine
DVT scanning, the DVT proportion was 2.3% (68/2,896;
Table 6) [12-15,17,19,23,26,28,29]. The DVT proportion
was significantly higher in patients undergoing routine
DVT surveillance scanning (relative risk 2.3 (95% CI 1.6 to
34); P < 0.0001).
Discussion
Spontaneous intracranial hemorrhage expansion at
24 hours
Spontaneous ICH expansion proportions at 24 hours
come from studies investigating chemoprophylaxis out-
comes and from other investigations where there was no
intent to assess chemoprophylaxis sequelae. The ICH
expansion proportion at 24 hours in investigations with-
out the intent to assess the impact of chemoprophylaxis
was twice that of studies directed at evaluating post-
chemoprophylaxis ICH expansion. Virtually all patients
in studies without the intent to assess the impact of
chemoprophylaxis on ICH expansion had ICH on the
initial CT scan. In contrast, the initial ICH proportion
for the chemoprophylaxis studies was commonly <100%
or not documented. In the three chemoprophylaxis studies









Arnold et al. [28] No E 8 99 2 2.0
Cothren et al. [21] No L 3 174 0 0.0
Depew et al. [22] No E ≤2 29 1 3.5
Depew et al. [22] No E >3 53 2 3.8
Dudley et al. [17] Yes L 3 287 1 0.3
Kim et al. [18] Yes H ≤3 47 0 0.0
Kleindienst et al. [23] No L 1 271 0 0.0
Koehler et al. [19] Yes L 3 268 4 1.5
Koehler et al. [19] Yes L 5 401 6 1.5
Kurtoglu et al. [20] Yes L 1 60 1 1.7
Levy et al. [11] Yes L 3 221 36 16.3
Levy et al. [11] No L 3 163 15 9.2
Minshall et al. [12] Yes L 2 158 8 5.1
Minshall et al. [12] Yes H 2 171 20 11.7
Norwood et al. [24] No L 1 36 0 0.0
Norwood et al. [24] No L 1 19 0 0.0
Norwood et al. [13] No L 1 150 6 4.0
Norwood et al. [14] No L 2 525 18 3.4
Pahatouridis et al. [25] No L 1 61 0 0.0
Phelan et al. [26] No L 1 34 2 5.9
Phelan et al. [26] No L 4 28 1 3.6
Saadeh et al. [15] Yes L 2 46 0 0.0
Saadeh et al. [15] Yes L ≥3 47 0 0.0
Salottolo et al. [27] No L <3 108 7 6.5
Salottolo et al. [27] No L ≥3 147 21 14.3
Scudday et al. [29] No E 4 402 11 2.7
Total 4,005 162 4.0
Early ↑ ICH, included patients with pre-chemoprophylaxis intracranial hemorrhage
(ICH) expansion; ↑ ICH, post-CP intracranial hemorrhage expansion; CP,
chemoprophylaxis; E, either unfractionated heparin or low molecular weight
heparin; H, unfractionated heparin; L, low molecular weight heparin.
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expansion proportion at 24 hours was substantially less,
compared with the studies without the intent to assess
chemoprophylaxis sequelae. This suggests that the patient
cohort traits for the two groups of studies are at variance;
specifically, patients undergoing pre-chemoprophylaxis
analysis were likely biased by the various inclusion and
exclusion criteria used.
Spontaneous intracranial hemorrhage expansion
proportions with delineated timelines
Phelan and colleagues provided insight into spontaneous
ICH progression without bias from multiple exclusion
criteria [16]. Virtually all patients with low-risk ICH had
suffered spontaneous ICH expansion at 48 hours post-injury. Conversely, a substantial portion of patients with
moderate or high-risk ICH developed ICH expansion >72
hours post-injury. These findings suggest that chemo-
prophylaxis would be reasonable in low-risk ICH patients
with a stable brain CT at 48 hours. However, in those with
moderate or high risk ICH, chemoprophylaxis would not
be appropriate until >72 hours post-injury.
Post-chemoprophylaxis intracranial hemorrhage
expansion proportions
The comprehensive literature search found investigations
describing ICH expansion proportions following chemo-
prophylaxis for 4,000 patients. For the 10 cohorts described
in seven studies that included some patients with pre-
chemoprophylaxis ICH expansion, the post-chemopro-
phylaxis ICH proportion was significantly greater
when chemoprophylaxis was given on post-injury days
1 to 3 (5.6%) compared with chemoprophylaxis given
after day 3 (1.5%). Therefore, chemoprophylaxis during
the 72 hours post-injury was associated with a risk of
post-chemoprophylaxis ICH expansion in patients with
spontaneous pre-chemoprophylaxis ICH expansion. The
pre-chemoprophylaxis ICH proportion ranged from 85 to
100% in 8 of the 10 study cohorts investigated; however,
the proportion was not documented or was <85% in the
other two cohorts. Most of the studies excluded very few
critical patients; alternatively, one study [19] excluded
patients requiring an intracranial pressure device and
another investigation [20] excluded those requiring
craniotomy. This implies that chemoprophylaxis during
the first 72 hours increases the risk for post-chemo-
prophylaxis expansion in patients with ICH on the initial
CT, especially when there has been pre-chemoprophylaxis
ICH expansion.
The investigations that excluded patients with pre
chemoprophylaxis ICH expansion indicated that the
post-chemoprophylaxis ICH proportion was similar
when chemoprophylaxis was given on post-injury days 1
to 3 (3.1%) compared with chemoprophylaxis given after
day 3 (2.8%). Of the 14 relevant cohorts in 12 studies,
the initial CT ICH proportion ranged from 93 to 100%
in five cohorts and <80% in two cohorts; these data were
not stipulated in the other seven cohorts. Within the 14
cohorts, GCS documentation noted severe brain injury in
two and non-severe brain injury in seven; the GCS was
not documented in five. Half of the cohorts excluded
patients with large, complex ICH [13,14,22,26,28,29].
Overall, these findings suggest that chemoprophylaxis
during the 72 hours post-injury is unlikely to cause post-
chemoprophylaxis ICH expansion when patients with
complex ICH or spontaneous pre-chemoprophylaxis ICH
expansion are excluded.
An investigation of diffuse axonal injury showed that
ICH expansion, if it were to occur, would develop within
Table 6 Deep vein thrombosis proportions
Study Agent IPC IPCdur CP day RS Number DVT Percentage
Arnold et al. [28] H Yes NS 8 No 47 8 17.0
Arnold et al. [28] L Yes NS 8 No 52 6 11.5
Depew et al. [22] E Yes Amb <3 Yes 29 4 13.8
Depew et al. [22] E Yes Amb >3 Yes 53 6 11.3
Depew et al. [22] N Yes Amb None ?? 42 0 0.0
Dudley et al. [17] L Yes Amb 3 No 287 21 7.3
Kim et al. [18] H Yes Amb ≤3 Yes 47 2 4.3
Kim et al. [18] H Yes Amb >3 Yes 17 1 5.9
Kleindienst et al. [23] L CS Amb 1 No 280 0 0.0
Koehler et al. [19] L NS NS 3 No 268 4 1.5
Koehler et al. [19] L NS NS 5 No 401 14 3.5
Kurtoglu et al. [20] L Yes NS 1 Yes 60 3 5.0
Kurtoglu et al. [20] N Yes NS None Yes 60 4 6.7
Levy et al. [11] L Yes Amb 3 Yes 221 13 5.9
Levy et al. [11] N Yes Amb None Yes 119 2 1.7
Minshall et al. [12] N Yes NS None No 57 1 1.8
Minshall et al. [12] L Yes NS 2 No 158 1 0.6
Minshall et al. [12] H Yes NS 2 No 171 2 1.2
Norwood et al. [13] L Yes CP 1 No 150 2 1.3
Norwood et al. [14] L NS NS 2 No 525 6 1.1
Phelan et al. [26] L NS NS 1 No 34 0 0.0
Phelan et al. [26] L NS NS 4 No 28 1 3.6
Saadeh et al. [15] L Yes NS 2 No 46 0 0.0
Saadeh et al. [15] L Yes NS ≥3 No 47 0 0.0
Salottolo et al. [27] N Yes NS None Yes 225 4 1.8
Salottolo et al. [27] L Yes NS <3 Yes 108 5 4.6
Salottolo et al. [27] L Yes NS ≥3 Yes 147 3 2.0
Scudday et al. [29] E Yes NS 4 No 402 3 0.8
Scudday et al. [29] N Yes NS None Yes 410 11 2.7
Total 4,491 127 2.8
Amb, until ambulating; CP, chemoprophylaxis; CS, compression stockings; DVT, deep vein thrombosis ; E, either unfractionated heparin or low molecular weight
heparin; H, unfractionated heparin; IPC, intermittent pneumatic compression devices; IPCdur, intermittent pneumatic compression duration; L, low molecular
weight heparin; NS, not stated; RS, routine deep vein thrombosis surveillance.
Table 7 Deep vein thrombosis proportions according to
chemoprophylaxis timing
CP day Number DVT Percentage 95% CI
Not given 913 22 2.4% 1.5-3.6%
Days 1 to 3 2,384 63 2.6% 2.1-3.4%
Days 4 or 5 831 18 2.2% 1.4-3.4%
Day 8 99 14 14.1% 8.6-22.4%
CP, chemoprophylaxis; CI, confidence interval; DVT, deep vein thrombosis.
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post-injury day 4 had a subsequent ICH expansion pro-
portion that was negligible, implying that chemoprophy-
laxis is reasonable for diffuse axonal injury on day 4.
Still, chemoprophylaxis timing should be customized for
those with ICH expansion.
When compared with LMWH, post-chemoprophylaxis
ICH expansion was greater with unfractionated heparin.
This suggests that LMWH is preferable in TBI patients.
Deep vein thrombosis proportions
We considered the DVT proportions cited in the post-
chemoprophylaxis ICH expansion studies to be the most
Abdel-Aziz et al. Critical Care  (2015) 19:96 Page 8 of 10germane to our literature review. Collectively, the publi-
cations describe a DVT proportion experience for over
4,000 patients. In the methodology section, most of the
studies indicated that intermittent pneumatic compres-
sion devices were used, implying that the majority of the
patients had those devices applied. The DVT propor-
tions were 2.4% for patients where chemoprophylaxis
was inappropriate, 2.6% with chemoprophylaxis given on
post-injury days 1 to 3, and 3.4% with chemoprophylaxis
given after post-injury day 3. Since these proportions are
neither statistically nor clinically different, we can infer
that a delay in chemoprophylaxis administration until
after post-injury day 3 is not detrimental. Conversely,
Arnold and colleagues [28] indicated that a delay in
chemoprophylaxis administration until post-injury day 8
is associated with an increase in DVT. Statements in the
discussion section indicate that the authors have revised
their practice to provide earlier chemoprophylaxis, fol-
lowing review of their data results and recent relevant
literature. Delays in chemoprophylaxis during the study
period likely represented an institutional perception that
earlier administration was risky in patients with ICH and
without substantial value.
The DVT proportions for patients receiving unfractio-
nated heparin or LMWH were similar, implying that
neither drug is more or less efficacious. DVT proportions
were higher in studies utilizing a routine DVT surveillance
process compared with DVT assessment only for patients
with clinical manifestations.
Because the 54% head injury DVT proportion reported
by Geerts and colleagues is at odds with the current
review, certain study features are worth elucidating [3].
Initially 716 trauma patient admissions with an Injury
Severity Score ≥9 were screened, but half of those were
excluded because they did not undergo contrast venog-
raphy, or the venogram was inadequate (n = 367). Thus,
they described the results of 349 patients who had a
good-quality lower-extremity contrast venogram 14 to
21 days after admission or earlier if the hospital stay was
<14 days. All patients had impedance plethysmography
performed every other day and daily clinical surveillance
for DVT. Of the 349 patients, 91 (26.1%) had a major
head injury. Although these study features indicate an
admirable and concerted effort to comprehensively
define accurate DVT proportions, certain caveats are
worth noting. First, the methodology clearly states that
patients did not receive mechanical or pharmacologic
antithrombotic prophylaxis during the study. Second,
only 1.5% (3/201) of all trauma patients with a DVT by
venography had clinical signs of DVT. Third, although
the head injury patients had a 54% overall DVT propor-
tion, the incidence of proximal DVT was substantially
lower at 19.8% (18/91). Fourth, when compared with the
final study group (n = 349), the 367 patients originallyexcluded from the study were younger, had less severe
injuries, and were less likely to have injuries predictive
of DVT. Geerts and colleagues’ study, in concert with
the current literature review, suggests that head injury
intermittent pneumatic compression devices are effective
in mitigating DVT and lengthy delays in administering
chemoprophylaxis increases DVT proportions. Lastly,
both investigations indicate that DVT proportions are
likely to increase when routine DVT surveillance is used.
Complementary review
Of importance is a recent systematic literature review to
assess effectiveness and safety of pharmacologic and
mechanical prophylaxis, and the optimal time to initiate
pharmacologic prophylaxis in TBI [30]. The authors found
that evidence existed that enoxaparin reduced rates of
DVT and unfractionated heparin reduced rates of mortal-
ity compared with no chemoprophylaxis in TBI. They
found that the evidence was insufficient to comment on
the effectiveness of chemoprophylaxis for DVT started
<72 hours versus >72 hours; however, absolute reported
proportions were similar. The review indicated that there
was insufficient evidence to comment on the effectiveness
and safety of mechanical strategies on venothrombo-
embolism outcomes. We believe that Chelladurai and col-
leagues’ literature review [30] and the current systematic
literature synthesis should be considered as complemen-
tary efforts.
Study limitations
There are several limitations in many of the studies used
in this analysis. An adequate assessment of TBI severity
(that is, GCS, head AIS, and percentage with ICH) was
not always available to determine whether groups under-
going one intervention or another were matched for se-
verity of illness. The method used for detecting ICH
progression was not always clear; therefore, differences
may exist depending on whether only radiology reports
were used or scans were re-reviewed by a dedicated neu-
roradiologist, based on specific a priori criteria. Certain
studies were biased because attending physicians ex-
cluded some patients because of their concern for ICH
expansion with early chemoprophylaxis. DVT propor-
tions may have been underestimated because lower
extremity ultrasound is unable to interrogate the pelvic
veins and the procedure was often not routine. Some
studies that failed to demonstrate intergroup differences
were underpowered, representing a potential type II
error regarding chemoprophylaxis risks or benefits.
Therefore, a large randomized, multicenter trial of TBI
patients is encouraged to enhance practice management
guidelines. Patients should be matched for severity of
illness, brain CT and DVT monitoring should be rou-
tine, patient selection criteria should be defined, and an
Abdel-Aziz et al. Critical Care  (2015) 19:96 Page 9 of 10investigation methodology should be organized to delin-
eate effective chemoprophylaxis drugs, timing, and
doses.
Conclusion
The spontaneous ICH expansion proportion at 24 hours
for investigations without the intent to assess the impact
of chemoprophylaxis was twice that of studies directed
at evaluating post-chemoprophylaxis ICH expansion. Thus,
patients undergoing pre-chemoprophylaxis analysis are
likely biased by the various inclusion and exclusion criteria
used in those studies. According to the literature, chemo-
prophylaxis during the first 72 hours is not appropriate
for patients with spontaneous ICH expansion or for
patients with moderate- or high-risk ICH. There is also
evidence that chemoprophylaxis after 48 hours post-injury
is unlikely to cause post-chemoprophylaxis ICH expansion
when patients with complex ICH or spontaneous pre-
chemoprophylaxis ICH expansion are excluded. In pa-
tients with diffuse axonal injury, while the literature
implies that DVT chemoprophylaxis is reasonable on day
4, chemoprophylaxis timing should be customized for
those with ICH expansion. Lower ICH expansion with
LMWH indicates that it is preferred over unfractionated
heparin for chemoprophylaxis in TBI patients. Further-
more, the evidence implies that DVT proportions do not
increase when chemoprophylaxis administration is de-
layed until post-injury day 4 or 5; however, the proportion
significantly increases after 7 days. The literature review
suggests that intermittent pneumatic compression devices
are effective in mitigating DVT. In addition, neither
unfractionated heparin nor LMWH is more or less effica-
cious for preventing DVT. Finally, the review indicates
that DVT proportions are increased when routine surveil-
lance techniques are used.
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